Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $155,200.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $3.88, for a total value of $155,200.00. Following the sale, the director owned 6,068,287 shares in the company, valued at $23,544,953.56. This trade represents a 0.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, October 6th, Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $4.84, for a total value of $242,000.00.
• On Tuesday, September 1st, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.34, for a total value of $100,200.00.

Recursion Pharmaceuticals Stock Performance

RXRX traded up $0.20 during trading on Wednesday, hitting $3.88. 20,553,455 shares of the stock were exchanged, compared to its average volume of 19,663,393. The firm has a market capitalization of $2.08 billion, a P/E ratio of -4.31 and a beta of 1.15. Recursion Pharmaceuticals, Inc. has a 1-year low of $2.77 and a 1-year high of $5.24. The stock has a fifty day moving average price of $3.76 and a two-hundred day moving average price of $3.53. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Monday, November 2nd. The company reported ($0.22) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.22). The company had revenue of $18.55 million during the quarter, compared to analysts’ expectations of $14.81 million. Recursion Pharmaceuticals had a negative return on equity of 46.47% and a negative net margin of 697.15%. During the same quarter in the previous year, the business earned ($0.36) earnings per share. As a group, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -0.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

RXRX has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Monday, October 19th. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, October 15th. Finally, Morgan Stanley set a $5.90 price objective on shares of Recursion Pharmaceuticals in a research report on Friday, October 16th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.18.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. First Trust Advisors LP increased its stake in shares of Recursion Pharmaceuticals by 15.2% during the first quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock worth $8,015,000 after acquiring an additional 344,035 shares during the period. Bank of America Corp DE raised its holdings in Recursion Pharmaceuticals by 18.2% during the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock worth $7,665,000 after purchasing an additional 384,486 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Recursion Pharmaceuticals during the first quarter worth about $7,370,000. Bank of New York Mellon Corp raised its holdings in Recursion Pharmaceuticals by 29.3% during the first quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock worth $4,490,000 after purchasing an additional 331,048 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its position in Recursion Pharmaceuticals by 537.3% in the fourth quarter. Hsbc Holdings PLC now owns 818,316 shares of the company’s stock valued at $3,367,000 after purchasing an additional 689,903 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.